| 摘要 |
Unit comprising neramexane, a pharmaceutically acceptable salt, solvate, conjugate, prodrug, polymorphic form, isomer, or derivative thereof; and a release-controlling excipient; wherein said unit has a diameter of from 0.1 to less than 6 mm. |
| 主权项 |
1. A unit comprising neramexane, a pharmaceutically acceptable salt, solvate, conjugate, prodrug, polymorphic form, isomer, or derivative thereof; and at least one release-controlling excipient; wherein the unit has a diameter of from 0.1 to less than 6 mm,
wherein the unit comprises a solid matrix comprising neramexane, a pharmaceutically acceptable salt, solvate, conjugate, prodrug, polymorphic form, isomer, or derivative thereof embedded or dispersed in the solid matrix; wherein the solid matrix is coated with the at least one release-controlling excipient; and wherein the at least one release-controlling excipient used for the coating comprises at least one first release-controlling excipient which is a non-ionic poly(meth)acrylate ester, and at least one second release-controlling excipient, which is hydroxypropylmethylcellulose, wherein the weight ratio of the at least one first release-controlling excipient to the at least one second release-controlling excipient is in the range of from 20:1 to 1:1:1 and the weight of the at least one first release-controlling excipient ranges from 2 to 25% based on the total weight of the unit. |
